Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Leadership changes at Roche

<< Previous

Bullboard Posts

Next >>

Post by PeteZerriaon Dec 12, 2022 1:25pm

178 Views

Post# 35166507

Leadership changes at Roche

Roche's head of pharmaceuticals to leave company

ZURICH, Dec 12 (Reuters) - Roche (ROG.S) said on Monday the head of its pharmaceuticals division had decided to leave after 16 years with the Swiss drugmaker, heralding a wider reshuffle in addition to a planned CEO changeover early next year.

Bill Anderson, the former boss of Roche's Genentech unit, would quit at the end of the year "to pursue opportunities outside of Roche", with a successor due to be named by March 2023, Roche said in a statement.

More: https://www.reuters.com/business/healthcare-pharmaceuticals/roche-names-new-ceo-with-schwan-set-become-chairman-2022-12-12/

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects